ETON - CIK 0001710340
The table below shows Eton Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $7.41M | $2.09M | -$2.47M | -$1.55M | $1.22M | $3.71M |
| Capital expenditure | $75.00K | $0.00 | $14.00K | $0.00 | $15.00K | - |
| Investing cash flow | -$15.07M | $0.00 | -$1.88M | $0.00 | -$15.00K | - |
| Dividends paid | - | - | - | - | - |
Eton Pharmaceuticals, Inc. reported operating cash flow of $10.52M for fiscal year 2025. That is up 986.1% from $969.00K in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$8.14M (FY 2018) to $10.52M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $1.39M | $394.00K | -$378.00K | -$49.00K | -$385.00K | $103.00K |